Discussions to date in relation to pro-survival proteins have centred on drugs targeting Bcl-2 e.g. Venetoclax. Bcl-2 keeps cells alive by binding to and suppressing BIM which triggers cell death. From what I understand, Bcl-2 is actually a family of proteins which also include Mcl-1 and Bcl-x.
One of the presentations at the 29th Lorne Cancer Conference 2017 held in February was, Which pro-survival BCL-2 family member should be targeted for the treatment of which cancer? The presentation was by Andreas Strasser from the Walter+Eliza Hall Institute. It would appear that Mcl-1 is critically important in a range of cancers including c-Myc driven malignant lymphoma.
The importance of Mcl-1 hasn't escaped the notice of Doug Fairlie.
Fairlie contributed to the research paper, MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib, published in December 2016. The data from the study provided the first evidence that Mcl-1 drives breast cancer cell invasion and that Mcl-1 antagonists could be used alone or in combination to suppress metastasis.
The work by Fairlie is being progressed through the project funded by NHMRC, a collaboration between Phylogica, ONJCRI and others. If you refer to the Phylogica announcement of 5 December 2016, you will note that the pro-survival proteins of interest include Mcl-1.
The presentation by Phylogica from January 2017 includes slide 56 titled Synergistic targeting of Myc and pro-survival proteins. The dot point of interest is FPP-Bim targets all pro-survival proteins: Bcl-2, Bcl-x and Mcl-1.
Do we deduce that the FPP-Bim can simultaneously target all pro-survival proteins? This could be big.
- Forums
- ASX - By Stock
- PYC
- BIM is Big
BIM is Big
-
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PYC (ASX) to my watchlist
|
|||||
Last
10.0¢ |
Change
-0.005(4.76%) |
Mkt cap ! $466.6M |
Open | High | Low | Value | Volume |
11.0¢ | 11.0¢ | 10.0¢ | $296.0K | 2.833M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
22 | 793740 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 281215 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
22 | 793740 | 0.100 |
3 | 716341 | 0.099 |
6 | 485204 | 0.098 |
2 | 29485 | 0.097 |
2 | 255000 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 281215 | 6 |
0.110 | 398824 | 4 |
0.115 | 1306852 | 9 |
0.120 | 669510 | 6 |
0.125 | 255000 | 3 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online